Search
Secukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigationalSecukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque … [A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015).
Products: Verxant 300 mg / 2 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 1 adet, VERXANT 150 MG/1 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADETCandesartan cilexetil
go.drugbank.com/drugs/DB00796ApprovedInvestigationalCandesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents … It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.
Mixtures: Candesartan/Amlodipin 1A Pharma 8 mg/10 mg – Hartkapseln, Candesartan/Amlodipin 1A Pharma 16 mg/10 mg – HartkapselnCategories: Angiotensin 2 Receptor Blocker, P-glycoprotein inhibitorsSacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigationalAs a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects. … [A193671] One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) antibody with the topoisomerase I inhibitor SN-38.
Categories: Trop-2-Directed Monoclonal AntibodiesProducts: TRODELVY 200 MG İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇİN TOZ, 1 ADET, TRODELVY®Empagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalEmpagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart … [A203501] As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold).
Mixtures: GLYXAMBI® 10 MG/ 5 MG, GLYXAMBI® 10 MG/ 5 MGCategories: P-glycoprotein substrates, Sodium-Glucose Transporter 2 InhibitorsNeuropeptide Y receptor type 2
go.drugbank.com/bio_entities/BE0002419TargetHumansReceptor for neuropeptide Y (NPY) and peptide YY (PYY) (PubMed:7592910, PubMed:7559383, PubMed:35507650, PubMed:36525977, PubMed:38882210).
Polypeptides: Neuropeptide Y receptor type 2Adalimumab
go.drugbank.com/drugs/DB00051ApprovedInvestigational[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA.[A39983] This drug is frequently known as _Humira_. … A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available.[L45643,L45818].
Products: HUMİRA 20 MG/0,2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADET, AMGEVİTA 20 MG/0.4 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETPalbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigationalIt is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. … Palbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery.
Mixtures: REAMPLA®, REAMPLA®Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexBosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigationalPhiladelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein. … Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrileIsoprenaline
go.drugbank.com/drugs/DB01064ApprovedInvestigational[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. … Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion
Categories: Compounds used in a research, industrial, or household setting, Adrenergic beta-2 Receptor AgonistsSynonyms: N-isopropyl-β-dihydroxyphenyl-β-hydroxyethylamine, 1-(3,4-dihydroxyphenyl)-2-(isopropylamino)ethanolEtilefrine
go.drugbank.com/drugs/DB08985ApprovedWithdrawnEtilefrine is an adrenergic agonist that appears to interact with beta-1 and some alpha-adrenergic receptors. It has been used as a vasoconstrictor agent.
Categories: Compounds used in a research, industrial, or household setting, Adrenergic beta-1 Receptor AgonistsProducts: ETILEFRINACLORHIDRATO 10 MG /ML, ETILEFRINA CLORHIDRATO 10 MG/ ML